title: Multidisciplinary team-working indicators of good practice in the clinical management of EGFR-inhibitor dermatologic toxicities.
authors.forename: Ausilia Maria
authors.initials: AM
authors.lastname: Manganoni
authors.forename: Camillo
authors.initials: C
authors.lastname: Farisoglio
authors.forename: Vittorio
authors.initials: V
authors.lastname: Ferrari
authors.forename: Alberto
authors.initials: A
authors.lastname: Zaniboni
authors.forename: Giordano
authors.initials: G
authors.lastname: Beretta
authors.forename: Fausto
authors.initials: F
authors.lastname: Meriggi
authors.forename: Piergiacomo
authors.initials: P
authors.lastname: Calzavara-Pinton
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068818:Cetuximab; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D033183:Interdisciplinary Communication; D007641:Keratolytic Agents / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D010348:Patient Care Team; D020156:Salicylic Acid / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007641:Keratolytic Agents; D066246:ErbB Receptors; D020156:Salicylic Acid; D000068818:Cetuximab